• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

    5.305 -0.195 (-3.55%)
    Streaming Delayed Price Updated: 2:18 PM EDT, Aug 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,183,155
    Open 5.400
    Bid (Size) 5.300 (44,000)
    Ask (Size) 5.310 (1,200)
    Prev. Close 5.500
    Today's Range 5.200 - 5.460
    52wk Range 4.910 - 14.00
    Shares Outstanding 95,568,307
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Important Notice to Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Roblox Corporation (NYSE: RBLX); Symbotic Inc. (NASDAQ: SYM); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is Investigating Claims on Your
    From Grabar Law Office
    Via GlobeNewswire
    News headline image
    SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
    From Schall, Brown & Schwartz LLP
    Via GlobeNewswire

    Performance

    YTD
    -53.8%
    -53.8%
    1 Month
    -10.7%
    -10.7%
    3 Month
    -35.1%
    -35.1%
    6 Month
    -42.4%
    -42.4%
    1 Year
    -60.7%
    -60.7%

    More News

    Read More
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    ARS Pharma (SPRY) Q2 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Deadline on October 5, 2026
    Via NewMediaWire
    Topics Lawsuit Retirement
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on October 5, 2026
    Via NewMediaWire
    Topics Lawsuit Retirement
    News headline image
    SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
    From Schall, Brown & Schwartz LLP
    Via GlobeNewswire
    News headline image
    Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY): Bloom Energy Corporation (NYSE: BE); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on
    From Grabar Law Office
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ARS Pharmaceuticals and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf
    From Grabar Law Office
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Securities Class Action Deadline - Contact the Firm Before October 5, 2026
    Via NewMediaWire
    Topics Lawsuit Retirement
    News headline image
    ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript ↗
    Via Benzinga
    Topics Earnings
    News headline image
    ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Did You Lose Money Investing in ARS Pharmaceuticals Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against SPRY
    Via Newsfile
    Topics Lawsuit
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights
    Via NewMediaWire
    Topics Lawsuit Retirement
    News headline image
    SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
    From Schall, Brown & Schwartz LLP
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SPRY
    From DJS LAW GROUP
    Via Business Wire
    News headline image
    SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
    From Schall, Brown & Schwartz LLP
    Via Business Wire
    News headline image
    ARS PHARMACEUTICALS LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ARS Pharmaceuticals and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire

    Frequently Asked Questions

    Is ARS Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, ARS Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does ARS Pharmaceuticals, Inc. - Common Stock trade on?
    ARS Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock is SPRY on the Nasdaq Stock Market
    What is the current price of ARS Pharmaceuticals, Inc. - Common Stock?
    The current price of ARS Pharmaceuticals, Inc. - Common Stock is 5.305
    When was ARS Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of ARS Pharmaceuticals, Inc. - Common Stock was at 08/24/26 02:18 PM ET
    What is the market capitalization of ARS Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of ARS Pharmaceuticals, Inc. - Common Stock is 506.99M
    How many shares of ARS Pharmaceuticals, Inc. - Common Stock are outstanding?
    ARS Pharmaceuticals, Inc. - Common Stock has 507M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.